-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Downgrades Chemours to Neutral, Lowers Price Target to $18

Benzinga·08/10/2026 11:29:54
Listen to the news
UBS analyst Joshua Spector downgrades Chemours (NYSE:CC) from Buy to Neutral and lowers the price target from $29 to $18.